
Search Clinical Trials
Sponsor Condition of Interest |
---|
Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
Novartis Pharmaceuticals
Spinal Muscular Atrophy (SMA)
Spinal muscular atrophy (SMA) is a neurogenetic disorder caused by a loss or mutation in
the survival motor neuron 1 gene (SMN1) on chromosome 5q13, which leads to reduced SMN
protein levels and a selective dysfunction of motor neurons. SMA is an autosomal
recessive, early childhood disease with an1 expand
Spinal muscular atrophy (SMA) is a neurogenetic disorder caused by a loss or mutation in the survival motor neuron 1 gene (SMN1) on chromosome 5q13, which leads to reduced SMN protein levels and a selective dysfunction of motor neurons. SMA is an autosomal recessive, early childhood disease with an incidence of 1:10,000 live births. SMA is the leading cause of infant mortality due to genetic diseases. The purpose of this registry is to assess the long term outcomes of patients with SMA in the context of advances in treatment options and also to characterize and assess long-term safety and effectiveness of OAV-101. Type: Observational [Patient Registry] Start Date: Sep 2018 |
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Pa1
National Cancer Institute (NCI)
Locally Advanced Pancreatic Adenocarcinoma
Stage III Pancreatic Cancer AJCC v8
This phase I/II trial studies the safety, side effects and best dose of M3814 and to see
how well it works when given together with radiation therapy in treating patients with
pancreatic cancer that has spread to nearby tissue or lymph nodes (locally advanced).
M3814 may stop the growth of tumor ce1 expand
This phase I/II trial studies the safety, side effects and best dose of M3814 and to see how well it works when given together with radiation therapy in treating patients with pancreatic cancer that has spread to nearby tissue or lymph nodes (locally advanced). M3814 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Giving M3814 and hypofractionated radiation therapy together may be safe, tolerable and/or more effective than radiation therapy alone in treating patients with locally advanced pancreatic cancer. Type: Interventional Start Date: Jan 2021 |
A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients
McMaster University
Prostate Cancer
Cardiovascular Disease
RADICAL PC1 is a prospective cohort study of men with a new diagnosis of prostate cancer.
RADICAL PC2 is a randomized, controlled trial of a systematic approach to modifying
cardiovascular and lifestyle risk factors in men with a new diagnosis of prostate cancer. expand
RADICAL PC1 is a prospective cohort study of men with a new diagnosis of prostate cancer. RADICAL PC2 is a randomized, controlled trial of a systematic approach to modifying cardiovascular and lifestyle risk factors in men with a new diagnosis of prostate cancer. Type: Interventional Start Date: Oct 2015 |
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
Leland Metheny
Acute Lymphocytic Leukemia
This study has two phases, Phase I and Phase II. The main goal of the Phase I portion of
this research study is to see what doses post-transplant inotuzumab ozogamicin can safely
be given to subjects without having too many side effects.
The Phase II portion of this study is to see what side effec1 expand
This study has two phases, Phase I and Phase II. The main goal of the Phase I portion of this research study is to see what doses post-transplant inotuzumab ozogamicin can safely be given to subjects without having too many side effects. The Phase II portion of this study is to see what side effects are seen with medication after transplant. Inotuzumab ozogamicin is a combination of an antibody and chemotherapy which has been shown to have significant activity against relapsed/refractory acute lymphocytic leukemia (ALL). Inotuzumab ozogamicin is considered experimental in this study. Type: Interventional Start Date: Jul 2017 |
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA1
National Cancer Institute (NCI)
Metastatic Colorectal Adenocarcinoma
Stage IV Colorectal Cancer AJCC v7
This phase III trial studies how well combination chemotherapy, bevacizumab, and/or
atezolizumab work in treating patients with deficient deoxyribonucleic acid (DNA)
mismatch repair colorectal cancer that has spread from where it first started (primary
site) to other places in the body (metastatic)1 expand
This phase III trial studies how well combination chemotherapy, bevacizumab, and/or atezolizumab work in treating patients with deficient deoxyribonucleic acid (DNA) mismatch repair colorectal cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as fluorouracil, oxaliplatin, and leucovorin calcium, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab may stop or slow colorectal cancer by blocking the growth of new blood vessels necessary for tumor growth. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving combination chemotherapy, bevacizumab, and atezolizumab may work better in treating patients with colorectal cancer. Type: Interventional Start Date: Jan 2018 |
Muscle and Movement With Anti-Obesity Medications
University of Kansas Medical Center
Obesity and Overweight
The goal of this clinical trial is to learn about changes in body composition related to
obesity medication use, and whether aerobic or resistance exercise training will impact
these body composition changes. It will also provide information about whether aerobic or
resistance exercise training has1 expand
The goal of this clinical trial is to learn about changes in body composition related to obesity medication use, and whether aerobic or resistance exercise training will impact these body composition changes. It will also provide information about whether aerobic or resistance exercise training has additional benefits on other health and fitness measurements. The main questions it aims to answer are: - Is there a difference in the change in body composition (fat mass, lean mass, muscle mass, and bone content) between the standard medical care and the exercise conditions (aerobic training and resistance training)? - Is there a difference in the change in body weight and BMI between the standard medical care and the exercise conditions (aerobic training and resistance training)? - Is there a difference in the change in cardiorespiratory fitness between the standard medical care and the exercise conditions (aerobic training and resistance training)? - Is there a difference in how much physical activity is completed between the standard medical care and the exercise conditions (aerobic training and resistance training)? - Is there a difference in the change in physical function between the standard medical care and the exercise conditions (aerobic training and resistance training)? - Is there a difference in the change in muscle strength between the standard medical care and the exercise conditions (aerobic training and resistance training)? - Is there a difference in the change in resting blood pressure between the standard medical care and the exercise conditions (aerobic training and resistance training)? - Is there a difference in the change in food intake between the standard medical care and the exercise conditions (aerobic training and resistance training)? - Is there a difference in the change in health-related quality of life between the standard medical care and the exercise conditions (aerobic training and resistance training)? Participants will: - Participate in an intervention for a period of 6 months that involves being assigned to a no exercise/standard medical care condition, or a supervised exercise condition (aerobic training or resistance training). - Visit the clinical before starting the study and at 6 months to complete study measurements of their body composition and other measurements to monitor their progress. - Complete a brief monitoring session at weeks 6, 12, and 18 across the 6 months. - Complete supervised exercise sessions at the research center 3x per week for 6 months (Participants in the exercise groups only: aerobic training or resistance training). Type: Interventional Start Date: Dec 2024 |
A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative1
Incyte Corporation
Myeloproliferative Neoplasms
This study is being conducted to assess the Safety, Tolerability, and Pharmacokinetics of
INCB160058 in Participants With Myeloproliferative Neoplasms. expand
This study is being conducted to assess the Safety, Tolerability, and Pharmacokinetics of INCB160058 in Participants With Myeloproliferative Neoplasms. Type: Interventional Start Date: Aug 2024 |
Study of Onvansertib in Combination with FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus F1
Cardiff Oncology
Metastatic Colorectal Cancer
CRC
KRAS/NRAS Mutation
The purpose of this study is to assess 2 different doses of onvansertib to select the
lowest dose that is maximally effective, and to assess the safety, efficacy,
pharmacokinetics, and pharmacodynamics of onvansertib in combination with FOLFIRI +
bevacizumab or FOLFOX + bevacizumab in patients with1 expand
The purpose of this study is to assess 2 different doses of onvansertib to select the lowest dose that is maximally effective, and to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of onvansertib in combination with FOLFIRI + bevacizumab or FOLFOX + bevacizumab in patients with KRAS or NRAS-mutated metastatic colorectal cancer (CRC) in the first-line setting. Type: Interventional Start Date: Feb 2024 |
SUBLOCADE Long-term Outcomes
Indivior Inc.
Opioid Use Disorder
This study will provide the opportunity to generate data on the long-term use of
SUBLOCADE under real-world conditions, and to observe enduring changes in lifestyle,
health, and sociodemographic factors that are part of the recovery process. Long-term
patterns of abstinence/opioid misuse as well as1 expand
This study will provide the opportunity to generate data on the long-term use of SUBLOCADE under real-world conditions, and to observe enduring changes in lifestyle, health, and sociodemographic factors that are part of the recovery process. Long-term patterns of abstinence/opioid misuse as well as measures of participants' physical, psychological, social, and economic well-being will be monitored to better understand factors associated with recovery from opioid use disorder (OUD). Therefore, this study will observe participants up to a maximum of 4 years. Type: Observational Start Date: Aug 2023 |
Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients W1
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm
Metastatic Malignant Solid Neoplasm
Unresectable Malignant Solid Neoplasm
This phase II trial tests whether ZEN003694 (ZEN-3694) in combination with talazoparib
works to shrink tumors in patients with solid tumors that are unlikely to be cured or
controlled with treatment and that may have spread from where it first started to nearby
tissue, lymph nodes, or distant parts1 expand
This phase II trial tests whether ZEN003694 (ZEN-3694) in combination with talazoparib works to shrink tumors in patients with solid tumors that are unlikely to be cured or controlled with treatment and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Another aim of this study is to find out if, and how, patients' genes influence their response to this specific drug combination. For this part of the study, investigators will run tests using samples of patients' tumor tissue and blood that will be collected during the study. ZEN-3694 is an inhibitor of a family of proteins called the bromodomain and extra-terminal (BET). It may prevent the growth of tumor cells that overproduce BET protein. Talazoparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Genes are pieces of the DNA code that individuals inherit from their parents. Some genes work to protect against cancer by correcting damage that can occur in the DNA when cells divide. BRCA1 and BRCA2 are two examples of these types of genes, and they are called tumor-suppressor genes. For example, if a person has a mutation in a BRCA1/2 gene they have a greatly increased risk of developing breast and ovarian cancer because their cells may no longer be able to completely repair damaged DNA. It is the accumulation of DNA damage which causes a cell to change into a cancerous cell. Other genes are also involved in this process, and these are called DNA damage repair genes. The KRAS mutation is a change in a protein in normal cells. Normally KRAS serves as an information hub for signals in the cell that lead to cell growth, but when there is a mutation in KRAS it signals too much and cells grow without being told to, which causes cancer. Combination therapy with ZEN-3694 and talazoparib may be effective at slowing or stopping tumor growth in patients with advanced cancer. Type: Interventional Start Date: Nov 2022 |
Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT1
Ono Pharmaceutical Co. Ltd
Refractory Primary Central Nervous System Lymphoma
Primary CNS Lymphoma
This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib
monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in
combination with one of two different high dose methotrexate based regimens
(methotrexate/ temozolomide/rituximab or rituximab/1 expand
This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in combination with one of two different high dose methotrexate based regimens (methotrexate/ temozolomide/rituximab or rituximab/methotrexate/procarbazine/ vincristine) as first line therapy in patients with newly diagnosed, treatment naïve PCNSL (Part B) Type: Interventional Start Date: Dec 2021 |
Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer
National Cancer Institute (NCI)
Recurrent Ovarian High Grade Serous Adenocarcinoma
Recurrent Platinum-Resistant Ovarian Carcinoma
This phase I/Ib trial identifies the side effects and best dose of abemaciclib when given
together with olaparib in treating patients with ovarian cancer that responds at first to
treatment with drugs that contain the metal platinum but then comes back within a certain
period (recurrent platinum-re1 expand
This phase I/Ib trial identifies the side effects and best dose of abemaciclib when given together with olaparib in treating patients with ovarian cancer that responds at first to treatment with drugs that contain the metal platinum but then comes back within a certain period (recurrent platinum-resistant). Abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Adding abemaciclib to olaparib may work better to treat recurrent platinum-resistant ovarian cancer. Type: Interventional Start Date: Jul 2021 |
The ENCIRCLE Trial
Edwards Lifesciences
Mitral Regurgitation
Mitral Valve Insufficiency
This study will establish the safety and effectiveness of the SAPIEN M3 System in
subjects with symptomatic, at least 3+ mitral regurgitation (MR) for whom commercially
available surgical or transcatheter treatment options are deemed unsuitable.
Following completion of enrollment, subjects will be1 expand
This study will establish the safety and effectiveness of the SAPIEN M3 System in subjects with symptomatic, at least 3+ mitral regurgitation (MR) for whom commercially available surgical or transcatheter treatment options are deemed unsuitable. Following completion of enrollment, subjects will be eligible for enrollment in the continued access phase of the trial. Type: Interventional Start Date: Nov 2020 |
Evaluating the Tolerability and Effects of Berberine on Major Metabolic Biomarkers: A Pilot Study
University of Kansas Medical Center
Metabolic Syndrome
Berberine is a dietary supplement that comes from the roots, stems, and bark of various
plants and has been used for centuries in traditional Chinese medicine. It may help lower
cholesterol, lower blood sugar, and reduce inflammation.Very few studies have been done
in the United States to show how1 expand
Berberine is a dietary supplement that comes from the roots, stems, and bark of various plants and has been used for centuries in traditional Chinese medicine. It may help lower cholesterol, lower blood sugar, and reduce inflammation.Very few studies have been done in the United States to show how berberine effects cholesterol and blood sugar. This study is looking to see how berberine changes cholesterol and blood sugar, and to see how well it is tolerated.Berberine is not a prescription medication but it appears to have similar actions to common prescription medications to lower cholesterol like statins, and to lower blood sugar like metformin. We are studying berberine to see if it may be a good option for people that do not want to take prescription medications. Type: Interventional Start Date: Aug 2019 |
Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Be1
National Cancer Institute (NCI)
Resectable Intrahepatic Cholangiocarcinoma
This phase II trial tests how well giving durvalumab with standard chemotherapy,
gemcitabine and cisplatin, before surgery works in treating patients with high risk liver
cancer (cholangiocarcinoma) that can be removed by surgery (resectable). Durvalumab is a
monoclonal antibody that may interfere1 expand
This phase II trial tests how well giving durvalumab with standard chemotherapy, gemcitabine and cisplatin, before surgery works in treating patients with high risk liver cancer (cholangiocarcinoma) that can be removed by surgery (resectable). Durvalumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving durvalumab with gemcitabine and cisplatin before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed in patients with high risk resectable cholangiocarcinoma. Type: Interventional Start Date: Jul 2024 |
A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitama1
Pfizer
Diffuse Large B-Cell Lymphoma
The purpose of this study is to learn about the effects of two study medicines
(maplirpacept [PF-07901801] and glofitamab) when given together for the treatment of
diffuse large B-cell lymphoma (DLBCL) that is relapsed or is refractory. Relapsed means
has returned after last treatment. Refractory m1 expand
The purpose of this study is to learn about the effects of two study medicines (maplirpacept [PF-07901801] and glofitamab) when given together for the treatment of diffuse large B-cell lymphoma (DLBCL) that is relapsed or is refractory. Relapsed means has returned after last treatment. Refractory means that it has not responded to last treatment. The two study medicines are given after a single dose of obinutuzumab which is the third study medicine. DLBCL is a type of non-Hodgkin lymphoma (NHL). NHL is a cancer of the lymphatic system. It develops when the body makes abnormal B lymphocytes. These lymphocytes are a type of white blood cell that normally help to fight infections. This study is seeking adult participants who: - Have histologically confirmed diagnosis of DLBCL - Have received at least two first lines of treatment for NHL. - Are unable or unwilling to undergo a stem cell transplant or CAR-T cell therapy. Stem cell transplant is a procedure in which a patient receives healthy blood-forming cells to replace their own stem cells that have been destroyed by treatment. A CAR-T therapy is a type of treatment in which a patient's T cells are changed in the laboratory so they will attack cancer cells. Everyone in this study will receive all three medicines at the study site by intravenous (IV) infusion which is given directly into a vein. The two study medicines (maplirpacept [PF-07901801] and glofitamab) will be given in 21-day cycles. At Cycle 0, participants will receive a single dose of obinutuzumab pre-treatment followed by two step-up doses of glofitamab. The combination of maplirpacept (PF-07901801) with glofitamab full dose will be administered for the first time at Cycle 1 Day 1. Maplirpacept (PF-07901801) will be given weekly for the first three cycles and then every three weeks. Glofitamab will be given every 3 weeks for approximately 9 months. Thereafter participants will continue to receive maplirpacept alone. Maplirpacept (PF-07901801) will be given at different doses to different participants. Everyone taking part will receive the same fixed doses of glofitamab and obinutuzumab studied in patients with DLBCL. The study will compare the experiences of people receiving different doses of maplirpacept (PF-07901801). This will help to determine what dose is safe and effective when given with the other 2 study medicines. Type: Interventional Start Date: Aug 2023 |
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participan1
Theravance Biopharma
Symptomatic Neurogenic Orthostatic Hypotension
MSA - Multiple System Atrophy
This is a Phase 3, multi-center, randomized withdrawal study to evaluate the efficacy and
durability of ampreloxetine in participants with MSA and symptomatic nOH after 20 weeks
of treatment. This study includes 4 periods: Screening, open label, randomized
withdrawal, and long-term treatment extens1 expand
This is a Phase 3, multi-center, randomized withdrawal study to evaluate the efficacy and durability of ampreloxetine in participants with MSA and symptomatic nOH after 20 weeks of treatment. This study includes 4 periods: Screening, open label, randomized withdrawal, and long-term treatment extension (LTE). Type: Interventional Start Date: Jun 2023 |
Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN S1
SWOG Cancer Research Network
Anatomic Stage I Breast Cancer AJCC v8
Anatomic Stage II Breast Cancer AJCC v8
Anatomic Stage III Breast Cancer AJCC v8
Hormone Receptor-Positive Breast Carcinoma
This phase III trial compares the effect of active symptom monitoring and patient
education to patient education alone in helping young women with stage I-III breast
cancer stay on their hormone therapy medicines. The patient education tool contains
interactive weblinks which provide patients with1 expand
This phase III trial compares the effect of active symptom monitoring and patient education to patient education alone in helping young women with stage I-III breast cancer stay on their hormone therapy medicines. The patient education tool contains interactive weblinks which provide patients with education material about breast cancer and side effects of therapy. Symptom monitoring is a weblink via email or text message with questions asking about symptoms. Hormone therapy for breast cancer can cause side effects, and may cause some women to stop treatment early. Asking about symptoms more often may help women keep taking hormone therapy medicines. Type: Interventional Start Date: Mar 2023 |
Assessment of CCM in HF with Higher Ejection Fraction
Impulse Dynamics
Heart Failure
Heart Failure with Preserved Ejection Fraction
Heart Failure with Mid Range Ejection Fraction
Heart Failure with Moderately Reduced Ejection Fraction
Diastolic Heart Failure
The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac
Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and
≤60%. expand
The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤60%. Type: Interventional Start Date: Feb 2022 |
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Inte1
National Cancer Institute (NCI)
Pancreatic Acinar Cell Carcinoma
Pancreatic Adenosquamous Carcinoma
Pancreatic Squamous Cell Carcinoma
Resectable Pancreatic Acinar Cell Carcinoma
Resectable Pancreatic Adenocarcinoma
This phase II trial investigates how well the addition of olaparib following completion
of surgery and chemotherapy works in treating patients with pancreatic cancer that has
been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or
PALB2. Olaparib is an inhibitor of PARP1 expand
This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Type: Interventional Start Date: Jun 2021 |
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutan1
Melanoma and Skin Cancer Trials Limited
Cutaneous Melanoma, Stage II
Patients with a primary invasive melanoma are recommended to undergo excision of the
primary lesion with a wide margin. There is evidence that less radical margins of
excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm
margin of excision of the primary lesion for1 expand
Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of the primary lesion for adult patients with stage II primary invasive cutaneous melanomas (AJCC 8th edition) to determine differences in disease-free survival. A reduction in margins is expected to improve patient quality of life. Type: Interventional Start Date: Dec 2019 |
ProACT Post-Approval Study
Uromedica
Stress Urinary Incontinence
The ProACT Post Approval Study is a 5-year prospective, open-label, multi-center study
designed to evaluate the long-term incidence of urethral stricture and device erosion
after ProACT implantation. In addition, the study will evaluate whether treatment with
ProACT affects clinical outcomes after1 expand
The ProACT Post Approval Study is a 5-year prospective, open-label, multi-center study designed to evaluate the long-term incidence of urethral stricture and device erosion after ProACT implantation. In addition, the study will evaluate whether treatment with ProACT affects clinical outcomes after subsequent SUI therapies. Type: Interventional Start Date: Feb 2019 |
MEASuRE: Metreleptin Effectiveness And Safety Registry
Aegerion Pharmaceuticals, Inc.
Generalised Lipodystrophy
Partial Lipodystrophy
The study is a post-authorization, prospective, voluntary registry of patients treated
with commercial metreleptin including, but not limited to, patients in the US and EEA. expand
The study is a post-authorization, prospective, voluntary registry of patients treated with commercial metreleptin including, but not limited to, patients in the US and EEA. Type: Observational [Patient Registry] Start Date: Oct 2016 |
Transduction of Sympathetic Neural Activity in Human Obesity Without Hypertension
University of Kansas Medical Center
Obesity
In addition to chronically elevated MSNA, there is a growing recognition that
hypertension in states of insulin resistance and obesity may also be attributed to an
increased vascular sensitivity to MSNA (1, 2, 13, 36-38). To study this phenomenon, we
quantify vascular sensitivity to MSNA using an i1 expand
In addition to chronically elevated MSNA, there is a growing recognition that hypertension in states of insulin resistance and obesity may also be attributed to an increased vascular sensitivity to MSNA (1, 2, 13, 36-38). To study this phenomenon, we quantify vascular sensitivity to MSNA using an innovative, moment-to-moment assessment of the blood pressure response following individual bursts of muscle sympathetic nerve activity (MSNA), (10, 11, 34, 37). This approach is termed 'sympathetic-vascular transduction (SVT).' We will examine the hypothesis that SVT is exaggerated in obesity and insulin resistance and is attenuated by suppression of oxidative stress. Oxidative stress is the overabundance of reactive oxygen species and is another hallmark of hypertension, obesity, and insulin resistance. Oxidative stress can be safely reduced via intravenous infusion of ascorbic acid (Vit C) (4, 28). Therefore, we will use a randomized, double-blinded, placebo-controlled approach to test the hypothesis that elevated SVT will be attenuated by suppression of oxidative stress via ascorbic acid I.V. infusion compared with saline I.V. infusion (placebo) in obese adults with insulin resistance. Our study will identify a unique mechanism that can be targeted to reduce the excessively high prevalence of hypertension and risk for CVD in obesity and insulin resistance. Type: Observational Start Date: Aug 2022 |
RECOVER-SLEEP: Platform Protocol
Duke University
Long COVID
Long COVID-19
Hypersomnia
Sleep Disturbance
The platform protocol is designed to be flexible so that it is suitable for a range of
study settings and intervention types. Therefore, the platform protocol provides a
general protocol structure that can be shared by multiple interventions and allows
comparative analysis across the interventions.1 expand
The platform protocol is designed to be flexible so that it is suitable for a range of study settings and intervention types. Therefore, the platform protocol provides a general protocol structure that can be shared by multiple interventions and allows comparative analysis across the interventions. For example, objectives, measures, and endpoints are generalized in the platform protocol, but intervention-specific features are detailed in separate appendices. This platform protocol is a prospective, multi-center, multi-arm, randomized controlled platform trial evaluating potential interventions for PASC-mediated sleep disturbances. The hypothesis is that symptoms of sleep and circadian disorders that emerge in patients with PASC can be improved by phenotype-targeted interventions. Specific sleep and circadian disorders addressed in this protocol include sleep-related daytime impairment (referred to as hypersomnia) and complex PASC-related sleep disturbance (reflecting symptoms of insomnia and sleep-wake rhythm disturbance). Type: Interventional Start Date: Jul 2024 |
- Previous
- Next